Harbin Gloria Pharmaceuticals Co Ltd (002437)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Harbin Gloria Pharmaceuticals Co Ltd (002437) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013450
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Harbin Gloria Pharmaceuticals Co Ltd (Harbin Gloria) is a pharmaceutical company that produces and markets nutritional drugs. The company’s products comprise pharmaceutical drugs for treating nutrition disorders, cardiovascular diseases, cancer and musculoskeletal disorders. Its pipeline products include lubiprostone, developed for chronic idiopathic constipation, opioid-induced constipation, irritable bowel syndrome with constipation in women. Harbin Gloria also offers SX-004 for the treatment of acute leukemias and solid tumors. The company collaborates with hospitals and institutions to carry out its research activities. Harbin Gloria is headquartered in Beijing, China.

Harbin Gloria Pharmaceuticals Co Ltd (002437) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Harbin Gloria Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Harbin Gloria Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Harbin Gloria Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Harbin Gloria Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Harbin Gloria Pharmaceuticals Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Harbin Gloria Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Harbin Gloria Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Arcus Biosciences Enters into Licensing Agreement with Wuxi Biologics and Harbin Gloria Pharma for GLS-010 11
Equity Offering 12
Harbin Gloria Pharma Raises USD3.7 Million in Private Placement of Shares 12
Harbin Gloria Pharma Completes Spin-Off of Two Subsidiaries 13
Harbin Gloria Pharma to Raise USD628.7 Million in Private Placement of Shares 14
Debt Offering 15
Harbin Gloria Pharma to Raise USD243 Million in Public Offering of Notes Due 2019 15
Harbin Gloria Pharma Raises USD72.8 Million in Public Offering of 5.1% Notes Due 2020 16
Harbin Gloria Pharmaceuticals Co Ltd – Key Competitors 17
Harbin Gloria Pharmaceuticals Co Ltd – Key Employees 18
Harbin Gloria Pharmaceuticals Co Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Harbin Gloria Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Harbin Gloria Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Harbin Gloria Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Harbin Gloria Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Harbin Gloria Pharmaceuticals Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Harbin Gloria Pharmaceuticals Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Harbin Gloria Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arcus Biosciences Enters into Licensing Agreement with Wuxi Biologics and Harbin Gloria Pharma for GLS-010 11
Harbin Gloria Pharma Raises USD3.7 Million in Private Placement of Shares 12
Harbin Gloria Pharma Completes Spin-Off of Two Subsidiaries 13
Harbin Gloria Pharma to Raise USD628.7 Million in Private Placement of Shares 14
Harbin Gloria Pharma to Raise USD243 Million in Public Offering of Notes Due 2019 15
Harbin Gloria Pharma Raises USD72.8 Million in Public Offering of 5.1% Notes Due 2020 16
Harbin Gloria Pharmaceuticals Co Ltd, Key Competitors 17
Harbin Gloria Pharmaceuticals Co Ltd, Key Employees 18
Harbin Gloria Pharmaceuticals Co Ltd, Other Locations 19

★海外企業調査レポート[Harbin Gloria Pharmaceuticals Co Ltd (002437)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mega First Corporation Bhd (MFCB):企業の財務・戦略的SWOT分析
    Summary Mega First Corporation Bhd (MFCB) is a diversified company. The company operates through its business divisions such as power generation, resources, and property development and investment. Its power generation business builds, owns, operates and maintains coal-fired heat and power plant. MF …
  • Entergy New Orleans Inc:電力:M&Aディール及び事業提携情報
    Summary Entergy New Orleans Inc (Entergy) a subsidiary of Entergy Corporation is an electric utility company that offers power distribution services. The company provides electric distribution, account management, payment options and services, community services, business and economic development. I …
  • The Goodyear Tire & Rubber Company:企業の戦略・SWOT・財務情報
    The Goodyear Tire & Rubber Company - Strategy, SWOT and Corporate Finance Report Summary The Goodyear Tire & Rubber Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Identiv Inc (INVE):企業の財務・戦略的SWOT分析
    Summary Identiv Inc (Identiv), formerly Identive Group Inc, is a technology company that offers physical security and secure identification solutions. The company’s products include trusted authentication solutions, identity solutions, physical access control solutions, premises access solutions, co …
  • Avon Rubber Plc (AVON):企業の財務・戦略的SWOT分析
    Avon Rubber Plc (AVON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Israel Chemicals Ltd (ICL):企業の財務・戦略的SWOT分析
    Israel Chemicals Ltd (ICL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Radboud University Nijmegen Medical Centre-製薬・医療分野:企業M&A・提携分析
    Summary Radboud University Nijmegen Medical Centre (Radboud UMC), a subsidiary of Radboud University is a university medical center that offers patient care, research, and scientific training services. The centre’s patient care services include basic care, tertiary care, top referral care, and trans …
  • Servest Group Ltd:企業の戦略的SWOT分析
    Servest Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Dalton Pharma Services-製薬・医療分野:企業M&A・提携分析
    Summary Dalton Pharma Services (Dalton) is a contract manufacturing company that offers discovery, development and contract manufacturing services. The company’s product categories include building blocks, coelenterazines, drugs and metabolites, glitazones, gmp APIs, excipients and reagents, heteroc …
  • Avery Dennison Corporation (AVY)-医療機器分野:企業M&A・提携分析
    Summary Avery Dennison Corporation (Avery Dennison) is a labeling and packaging materials and solutions provider. The company produces pressure-sensitive materials, tags, labels, tickets, and other converted products. It also manufactures and sells fasteners, tickets, tags, radio-frequency identific …
  • Quadrise Fuels International Plc (QFI)-石油・ガス分野:企業M&A・提携分析
    Summary Quadrise Fuels International Plc (QFI), formerly Zareba Plc, is an oil-in-water emulsified fuel developer that manufactures and markets MSAR (Multiphase Superfine Atomised Residue), an emulsion fuel as a low cost substitute for conventional heavy fuel oil (HFO) for use in power generation pl …
  • Rosseti (RSTI):企業の財務・戦略的SWOT分析
    Rosseti (RSTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • The Interpublic Group of Companies, Inc. (IPG):企業の財務・戦略的SWOT分析
    The Interpublic Group of Companies, Inc. (IPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • StageZero Life Sciences Ltd (GEN):企業の財務・戦略的SWOT分析
    Summary StageZero Life Sciences Ltd (StageZero Life Sciences) is a provider of molecular diagnostic products. The company develops and commercializes diagnostics and personalized medicine for cancer and other chronic diseases. Its Sentinel Principle is a novel approach to identifying biomarkers of b …
  • Trovagene Inc (TROV)-医療機器分野:企業M&A・提携分析
    Summary Trovagene Inc (Trovagene) is a development stage molecular diagnostic company focusing on the development and commercialization of proprietary molecular genetic detection technologies for screening and monitoring cancer and other diseases. Its product portfolio includes liquid biopsy tests t …
  • Phytel Inc-製薬・医療分野:企業M&A・提携分析
    Summary Phytel Inc (Phytel), a subsidiary of International Business Machines Corporation is an integrated population health management software and solutions provider. The company’s services include reduce total cost of care, prepare for value based care, increase patient engagement, measure quality …
  • Entravision Communications Corp (EVC):企業の財務・戦略的SWOT分析
    Entravision Communications Corp (EVC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Western Farmers Electric Cooperative:企業の戦略的SWOT分析
    Western Farmers Electric Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • EndoStim Inc:医療機器:M&Aディール及び事業提携情報
    Summary EndoStim Inc (EndoStim) is a medical device company that provides therapeutic solutions. The company develops and commercializes a neurostimulation system for the treatment of severe gastroesophageal reflux disease. It concentrates on the treatment of gastroesophageal reflux disease through …
  • CRH Medical Corp (CRH)-医療機器分野:企業M&A・提携分析
    Summary CRH Medical Corp (CRH Medical), formerly Medsurge Medical Products Corp is a medical device company that provides treatment of hemorrhoids. The company provides CRH O’Regan System, a hemorrhoid technology for treating hemorrhoid. It provides topical ointments and creams including preparation …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆